Citations

Clear

219 citation(s) found for "Do, Ron".

Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation
Hendifar, Andrew , Shroff, Rachna T. , Leichman, Lawrence, Epelbaum, Ron, Geva, Ravit , Kim, George , Wolff, Robert A. , Allen, Andrew R., Giordano, Heidi, Raponi, Mitch , Isaacson, Jeff, Rolfe, Lindsey, Vonderheide, Robert H. , Domchek, Susan M. , McWilliams, Robert R. , Alberts, Steven R. , Isaacson, Jeffrey D., Biankin, Andrew V.

Mayo Clinic

Cancer Research | October 5, 2015 | Volume: 75 | Issue: 13_Supplement | Pages: B102-B102

10.1158/1538-7445.panca2014-b102 Get It

Abstract Background: Despite the recent progress made with front-line treatment for advanced pancreatic cancer (PC), most patients (pts) will either relapse or be refractory to treatment. Others may not even be eligible due to the toxicity profile of the available options or due to clinical deterioration. Once the disease progresses following front-line treatment, there is no accepted standard of care. Treatment options are clearly needed for patients with refractory disease. Approximately 5% of unselected PC pts, 10% of PC patients of Ashkenazi Jewish descent, and up to 19% of familial PC cases, harbor a germline BRCA mutation. Though less well characterized to date, somatic BRCA mutations also appear to play a significant role in PC. Clinical data have shown that pts with BRCA-mutant (BRCAmut) tumors, including those with PC, respond to treatment with a PARP inhibitor (PARPi). Early data suggest that other genomic characteristics may be surrogate biomarkers of homologous recombination deficiency (HRD) and define a larger group of responders than just BRCA mutation(s) alone. Rucaparib, an oral PARPi, is being developed for treatment of cancers associated with HRD due to a BRCA mutation or other homologous recombination pathway defect. Rucaparib has a desirable PK profile, is well tolerated, and has demonstrated clinical activity (RECIST and/or CA-125 responses) in patients with BRCAmut pancreatic, ovarian, or breast cancer in an ongoing Phase 1/2 study (NCT01482715). Three studies are currently ongoing in ovarian cancer and a trial in BRCAmut pancreatic cancer is now planned. The clinical activity of PARPi, including rucaparib, in BRCAmut PC, combined with the paucity of active 2nd-line therapies, support evaluation of rucaparib in PC pts with a BRCA mutation. Methods: Study CO-338-023 (NCT02042378) is a single-arm, open-label Phase 2 trial of continuous monotherapy rucaparib in up to 100 pts with pancreatic ductal adenocarcinoma (or related subtype) who are known to harbor a deleterious BRCA mutation (germline or somatic). Pts must have received at least 1, but no more than 2, prior regimens for locally advanced or metastatic disease and have relapsed / progressive disease confirmed by radiologic assessment, or are no longer able to tolerate chemotherapy due to toxicity, and radiologic assessment confirms stable or progressive disease. Other key inclusion criteria include measurable disease, ECOG Performance Status 0 or 1, and adequate organ function. Pts with endocrine tumors or who received prior PARPi treatment are excluded. Pts will take 600 mg BID rucaparib continuously and be evaluated for safety every 2–4 wks, disease status (CT scans, CA19–9) every 4–8 wks until disease progression, and then for survival every 4 wks. Blood and archival tumor tissue (if available) will be collected from all pts. The primary endpoint is ORR by RECIST v1.1. Key secondary endpoints include duration of response, PFS, OS, and safety. Exploratory analyses include gene sequence and structural rearrangements of tumor DNA and evaluation of circulating tumor DNA. A group sequential interim monitoring plan will be implemented to stop the study early for either superior efficacy or futility. Interim analyses will occur after every 10th patient enrolled has sufficient disease assessment data available. If robust activity is observed in the BRCAmut PC population, the trial may be broadened to include PC pts with HRD due to other than a BRCA mutation. The trial will be open to enrollment at clinical sites in the US and Israel in 2Q 2014. Citation Format: Susan M. Domchek, Robert McWilliams, Andrew Hendifar, Rachna T. Shroff, Lawrence Leichman, Ron Epelbaum, Ravit Geva, George Kim, Steven R. Alberts, Robert A. Wolff, Andrew Allen, Heidi Giordano, Mitch Raponi, Jeff Isaacson, Lindsey Rolfe, Andrew Biankin, Robert H. Vonderheide. A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr B102.
Learning curves for transfemoral transcatheter aortic valve replacement in the PARTNER‐I trial: Success and safety
Minha, Sa’ar , Waksman, Ron , Satler, Lowell P., Torguson, Rebecca, Alli, Oluseun , Rihal, Charanjit S. , Mack, Michael J. , Svensson, Lars G. , Rajeswaran, Jeevanantham , Tuzcu, E. Murat , Thourani, Vinod H. , Makkar, Raj , Ehrlinger, John, Lowry, Ashley M. , Suri, Rakesh M. , Greason, Kevin L. , Leon, Martin B. , Holmes, David R. , Pichard, Augusto D., Rihal, Charanjit S. , Blackstone, Eugene H.

Mayo Clinic

Catheterization and Cardiovascular Interventions | October 1, 2015 | Volume: 87 | Issue: 1 | Pages: 165-175

10.1002/ccd.26121 | PMID 26425793 Get It

ObjectivesTo identify number of cases needed to maximize device success and minimize adverse events after transfemoral transcatheter aortic valve replacement (TF‐TAVR), and determine if adverse events were linked to the technical performance learning curve.BackgroundTF‐TAVR is a complex procedure with an incompletely characterized learning curve for clinical outcomes.MethodsFrom 4/2007–2/2012, 1521 patients underwent TF‐TAVR in the PARTNER‐I trial. Outcomes learning curves were defined as number of cases needed to reach a plateau for device success, adverse events, and post‐procedure length of stay. Institutional variation was accounted for by mixed‐model non‐linear techniques, which were also used to identify contribution of the procedure time learning curve to 30‐day major adverse events and length of stay.ResultsEighty percent device success was achieved after 22 cases; major vascular complications fell below 5% after 70 cases and major bleeding below 10% after 25 cases. It took an average of 28 cases to achieve a consistent low risk of 30‐day major adverse events, but institutions entering in the middle of the trial achieved it after about 26. The most significant correlate of 30‐day major adverse events and post‐procedure length of stay was procedure time (P < 0.0001). However, this association was related to patient and unmeasured variables, not the procedure time learning curve (P = 0.6).ConclusionsBy end of trial, a consistent low risk of adverse events was achieved after ∼26 cases. However, these improved results were due to change in patient risk profile; outcomes were not linked to the technical performance learning curve. © 2015 Wiley Periodicals, Inc.
Classification of current anticancer immunotherapies
Galluzzi, Lorenzo , Vacchelli, Erika , Pedro, José Manuel Bravo‐San , Buqué, Aitziber , Senovilla, Laura , Baracco, Elisa Elena, Bloy, Norma , Castoldi, Francesca , Abastado, Jean-Pierre, Agostinis, Patrizia , Apte, Ron N., Aranda, Fernando , Ayyoub, Maha , Beckhove, Philipp , Blay, Jean‐Yves , Bracci, Laura , Caignard, Anne , Cavallo, Federica , Celis, Estaban, Clayton, Aled , Coussens, Lisa M. , Dhodapkar, Madhav V. , Eggermont, Alexander , Fearon, Douglas T. , Fučíková, Jitka , Galon, Jérôme , Garg, Abhishek D. , Ghiringhelli, François , Gilboa, Eli , Gnjatic, Sacha , Hoos, Axel , Jäger, Dirk, Kaliński, Paweł , Kärre, Klas , Kepp, Oliver , Kiessling, Rolf , Klein, Eva, Knuth, Alexander, Lewis, Claire E. , Lugli, Enrico , Mach, J P, Mattei, Fabrizio , Mavilio, Domenico , Melero, Ignacio , Melief, Cornelis J.M., Moretta, Lorenzo , Odunsi, Adekunke, Palucka, A. Karolina, Porgador, Angel , Prendergast, George C. , Restifo, Nicholas P. , Rizvi, Naiyer A. , Schreiber, Hans , Seliger, Barbara , Shiku, Hiroshi , Špíšek, Radek , Srivastava, Pramod K. , Vile, Richard G. , Wagner, Hermann, Weber, Jeffrey S. , Zitvogel, Laurence , Zou, Weiping , Abastado, Jean‐Pierre, Castelli, Chiara , Cerundolo, Vincenzo , Colombo, Mario P. , Fridman, Wolf H. , Gabrilovich, Dmitry I. , Giaccone, Giuseppe , Hosmalin, Anne , Kirkwood, John M. , Liblau, Roland , Lotze, Michael T. , Mittendorf, EA , Okada, Hideho , Peter, Marcus E. , Pienta, Kenneth J , Rabinovich, Gabriel A , Sautès‐Fridman, Catherine , Silva‐Santos, Bruno , Smyth, Mark J. , Speiser, Daniel E. , Talmadge, James E. , Tartour, Éric , Burg, Sjoerd H. van der , Eynde, Benoı̂t J. Van den , Whiteside, Theresa L , Wolchok, Jedd D. , Kroemer, Guido , Gnjatic, Sacha , Blay, Jean-Yves , Galon, Jerome , Weber, Jeffrey

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 5 | Issue: 24 | Pages: 12472-12508

10.18632/oncotarget.2998 | PMID 25537519 Get It

Learning curves for transfemoral transcatheter aortic valve replacement in the PARTNER‐I trial: Technical performance
Alli, Oluseun , Rihal, Charanjit S. , Suri, Rakesh M. , Greason, Kevin L. , Waksman, Ron , Minha, Sa’ar , Torguson, Rebecca, Pichard, Augusto D., Mack, Michael J. , Svensson, Lars G. , Rajeswaran, Jeevanantham , Lowry, Ashley M. , Ehrlinger, John, Tuzcu, E. Murat , Thourani, Vinod H. , Makkar, Raj , Leon, Martin B. , Holmes, David R. , Rihal, Charanjit S. , Blackstone, Eugene H.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 10, 2015 | Volume: 87 | Issue: 1 | Pages: 154-162

10.1002/ccd.26120 | PMID 26256280 Get It

ObjectivesTo assess technical performance learning curves of teams performing transfemoral transcatheter aortic valve replacement (TF‐TAVR).BackgroundTF‐TAVR is a new procedure for treating severe aortic stenosis. The number of cases required for procedural efficiency is unknown.MethodsIn the PARTNER‐I trial, 1,521 patients underwent TF‐TAVR from 4/2007–2/2012. Learning curve analysis of technical performance metrics was performed using institution‐specific patient sequence number, interval between procedures, and institutional trial entry date. Learning curve characteristics were assessed using semi‐parametric and parametric mixed‐effects models.ResultsAs patient sequence number increased, average procedure time decreased from 154 to 85 minutes (P < 0.0001), and fluoroscopy time from 28 to 20 minutes (P < 0.0001). Procedure time plateaued at an average of 83 minutes (range 52–140). Procedure time plateau was dynamic during the course of the trial, averaging 25 cases (range 21–52) by its end. The later institutions enrolled in the trial, the shorter the initial procedure time. During the trial, percutaneous rather than surgical access increased from 7.9% to 69%.ConclusionsTechnical performance learning curves exist for TF‐TAVR; procedural efficiency increased with experience, with concomitant decreases in radiation and contrast media exposure. The number of cases needed to achieve efficiency decreased progressively, with optimal procedural performance reached after approximately 25 cases for late‐entering institutions. Knowledge and experience accumulated by early TF‐TAVR institutions were disseminated, shortening the learning curve of late‐entering institutions. Technological advances resulting from learning during the trial moved the field from initial conservative surgical cut‐down to percutaneous access for most patients. © 2015 Wiley Periodicals, Inc.
Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003
Wagle, Nikhil , Richardson, Andrea L. , Forero‐Torres, Andres , Hobday, Timothy J. , Dees, Elizabeth Claire , Nanda, Rita , Rimawi, Mothaffar F. , Guo, Hao , Barry, William T., Bose, Ron , Shen, Wei , Gabriel, Stacey , Garraway, Levi A. , Krop, Ian E. , Lin, Nancy U. , Leshchiner, Ignaty , Mayer, Ingrid A. , Wolff, Antonio C. , Winer, Eric P. , Rimawi, Mothaffar

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 75 | Issue: 9_Supplement | Pages: PD3-5-PD3-5

10.1158/1538-7445.sabcs14-pd3-5 Get It

Abstract Background: Although the spectrum of genomic alterations in primary, treatment-naïve breast tumors has been described, the genomic landscape of HER2+ MBC remains underexplored. Furthermore, tumor genomic alterations that arise after progression on anti-HER2 therapy are largely unknown. Methods: We prospectively collected metastatic tumor biopsies from patients (pts) enrolled on TBCRC003 (NCT00470704), a phase II study evaluating the combination of lapatinib (L) and T in pts with HER2+ MBC who had varying degrees of prior T exposure. We performed WES on baseline metastatic biopsies and normal DNA from 57 pts. In 36 pts, we also performed WES on pre-treatment primary tumors. Tumors were analyzed for point mutations, insertions/deletions, and copy number alterations. Results: Total accrual was 116 pts. 87 pts were registered in one of two efficacy cohorts: Cohort 1 included pts w no prior T for MBC. Pts with prior adjuvant T were included if the interval from last T to 1st recurrence &gt; 12 months. Cohort 2 included pts with 1-2 prior lines of T for MBC or recurrence within 12 months of adjuvant T. An additional 29 pts were enrolled in a biomarker cohort (Cohort 3). Per-protocol efficacy analyses for 85 pts deemed evaluable are shown below: Objective Response RateClinical Benefit RateMedian Time to ProgressionCohort 150% (90% CI 33.8-66.2%)57.5% (95% CI 40.9-73.0)7.4 monthsCohort 222.2% (90% CI 11.2-37.1%)42.2% (95% CI 27.7-57.8)5.3 months As we previously reported (Wagle et al, ASCO 2014), across 57 metastatic tumors, significant recurrently mutated genes were TP53 (n=30; 53%) and PIK3CA (n=19; 33%). The frequency of mutant TP53 and PIK3CA was not significantly different from 119 primary, treatment-naïve HER2+ tumors sequenced in the TCGA study (50%, p=0.8 and 27%, p=0.5, respectively). Recurrent copy number alterations were also similar to TCGA data. Comparing the 38 pts who received any prior T with the 19 pts who did not, there was no significant difference in the incidence of mutant TP53 (53% vs 53%, p=1.0) and PIK3CA (37% vs 26%, p=0.6). We identified mutations in the HER2 kinase domain in 4/38 pts who received prior T (11%), as compared to 0/19 T-naïve pts. HER2 kinase domain mutations have been identified in ∼2% of HER2-negative cancers but &lt;1% of primary HER2+ cancers. 3 of the mutations were L755S, which has been shown to be resistant to L and sensitive to irreversible HER2 inhibitors. The 4th mutation was D742N, a novel kinase domain mutation. None of the 4 pts with HER2 kinase domain mutations had an objective response, though 1 pt had stable disease for 29 weeks. An analysis comparing paired archival primary tumors and baseline metastatic biopsies from 36 pts to identify genomic alterations acquired or enriched in the metastatic tumors will be presented. Conclusions: We present an analysis of the genomic landscape of HER2+ MBC, including comparisons between matched primary tumors and metastatic biopsies. Somatic HER2 kinase mutations in pts with HER2+ MBC treated with prior T suggests that these mutations may be involved in resistance to T, and may predict poor response to additional anti-HER2 therapy with combined L and T. Novel therapeutic approaches may be required for these pts. Citation Format: Nikhil Wagle, Nancy U Lin, Andrea L Richardson, Ignaty Leshchiner, Ingrid A Mayer, Andres Forero-Torres, Timothy J Hobday, Elizabeth C Dees, Rita Nanda, Mothaffar F Rimawi, Hao Guo, William T Barry, Ron Bose, Wei Shen, Antonio C Wolff, Stacey B Gabriel, Levi A Garraway, Eric P Winer, Ian E Krop. Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PD3-5.
Impedance, gas mixing, and bimodal ventilation in constricted lungs
Anafi, Ron C. , Beck, Kenneth C., Wilson, Theodore A., Anafi, Ron C

Mayo Clinic

Journal of Applied Physiology | March 3, 2015 | Volume: 94 | Issue: 3 | Pages: 1003-1011

10.1152/japplphysiol.00569.2002 | PMID 12571131 Get It

To evaluate the effect of increasing smooth muscle activation on the distribution of ventilation, lung impedance and expired gas concentrations were measured during a 16-breath He-washin maneuver in five nonasthmatic subjects at baseline and after each of three doses of aerosolized methacholine. Values of dynamic lung elastance (El,dyn), the curvature of washin plots, and the normalized slope of phase III ( S N ) were obtained. At the highest dose, El,dyn was 2.6 times the control value and S N for the 16th breath was 0.65 liter −1 . A previously described model of a constricted terminal airway was extended to include variable muscle activation, and the extended model was tested against these data. The model predicts that the constricted airway has two stable states. The impedances of the two stable states are independent of smooth muscle activation, but driving pressure and the number of airways in the high-resistance state increase with increasing muscle activation. Model predictions and experimental data agree well. We conclude that, as a result of the bistability of the terminal airways, the ventilation distribution in the constricted lung is bimodal.
The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Sanda, Martin G. , Broyles, Dennis L., Shin, Sanghyuk S. , Bangma, Chris H. , Wei, John T., Partin, Alan W. , Klee, George G., Slawin, Kevin M., Marks, Leonard S. , Schaik, Ron H. N. van , Chan, Daniel W. , Sokoll, Lori J. , Cruz, Amabelle B., Mizrahi, Isaac, Catàlona, William J. , Loeb, Stacy

Mayo Clinic

Journal of Urology | November 17, 2014 | Volume: 193 | Issue: 4 | Pages: 1163-1169

10.1016/j.juro.2014.10.121 | PMID 25463993 Get It

A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease
Casteleijn, Niek F. , Visser, Folkert W., Drenth, Joost P.H. , Groen, Gerbrand J. , Hogan, Marie C., Gansevoort, Ron T., Drenth, J.P.H., Fijter, J.W. de, Gansevoort, R.T., Peters, D.J.M., Wetzels, J., Zietse, R., Hogan, Marie C. , Gevers, Tom J.G. , Hogan, Marie C., Gansevoort, Ron T., Drenth, J.P.H., Fijter, J.W. de, Gansevoort, R.T., Peters, D.J.M., Wetzels, J., Zietse, R., Hogan, Marie C , Drenth, Joost P H

Mayo Clinic

Nephrology Dialysis Transplantation | August 27, 2014 | Volume: 29 | Issue: suppl_4 | Pages: iv142-iv153

10.1093/ndt/gfu073 | PMID 25165181 Get It

Cutaneous Injection of Human Subjects with Macrophage Inflammatory Protein-1α Induces Significant Recruitment of Neutrophils and Monocytes
Lee, Sang Chin, Brummet, Mary , Woodworth, Thasia , Leiferman, Kristin M. , Gilman, Steven C., Gladue, Ron P., Schleimer, Robert P. , Shahabuddin, Syed Khurram , Georas, Steve N. , Stellato, Cristiana , Beck, Lisa A.

Mayo Clinic

The Journal of Immunology | April 22, 2014 | Volume: 164 | Issue: 6 | Pages: 3392-3401

10.4049/jimmunol.164.6.3392 | PMID 10706735 Get It

Abstract Macrophage inflammatory protein (MIP-1α), a member of the CC chemokine subfamily, has been shown to attract T cells and monocytes in vitro and to be expressed at sites of inflammation. Although the in vitro activities of MIP-1α have been well documented, the in vivo biological activities of MIP-1α in humans have not been studied. To address this, we challenged human subjects by intradermal injection with up to 1000 pmol of MIP-1α and performed biopsies 2, 10, and 24 h later. Although no acute cutaneous or systemic reactions were noted, endothelial cell activation, as indicated by the expression of E-selectin, was observed. In agreement with its in vitro activity, monocyte, lymphocyte, and, to a lesser degree, eosinophil infiltration was observed, peaking at 10–24 h. Surprisingly, in contrast to its reported lack of in vitro neutrophil-stimulating activity, a rapid infiltration of neutrophils was observed in vivo. This neutrophil infiltration occurred as early as 2 h, preceding the appearance of other cells, and peaked at 10 h. Interestingly, we found that neutrophils in whole blood, but not after isolation, expressed CCR1 on their cell surface. This CCR1 was thought to be functional as assessed by neutrophil CD11b up-regulation following whole-blood MIP-1α stimulation. These studies substantiate the biological effects of MIP-1α on monocytes and lymphocytes and uncover the previously unrecognized activity of MIP-1α to induce neutrophil infiltration and endothelial cell activation, underscoring the need to evaluate chemokines in vivo in humans.
Recommendations for Nomenclature of the Insulin-Like Growth Factor Binding Protein Superfamily
Binoux, M, Clemmons, David R. , Conover, Cheryl A. , Drop, S. L. S., Holly, Jeff M.P. , Mohan, S., Oh, Youngman , Rosenfeld, Ron G. , Baxter, Robert C. , Mohan, Subburaman

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 139 | Issue: 10 | Pages: 4036-4036

10.1210/endo.139.10.5083 | PMID 9751479 Get It